X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (654) 654
Patent (192) 192
Publication (20) 20
Conference Proceeding (7) 7
Dissertation (4) 4
Technical Report (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (281) 281
female (149) 149
male (142) 142
oncology (141) 141
middle aged (124) 124
aged (110) 110
index medicus (110) 110
adult (100) 100
performing operations (80) 80
transporting (80) 80
chemistry (67) 67
expression (66) 66
hematology (63) 63
aged, 80 and over (62) 62
animals (62) 62
metallurgy (62) 62
cancer (61) 61
translocation, genetic (57) 57
gene (52) 52
physics (50) 50
prognosis (49) 49
lymphoma (44) 44
mice (44) 44
molecular sequence data (42) 42
genetics & heredity (39) 39
leukemia (39) 39
lymphoma, b-cell - genetics (39) 39
pathology (38) 38
chromosomes, human, pair 11 (37) 37
human necessities (37) 37
identification (37) 37
adolescent (36) 36
base sequence (36) 36
immunohistochemistry (36) 36
lymphomas (36) 36
genetic aspects (35) 35
physical or chemical processes or apparatus in general (34) 34
hemic and lymphatic diseases (33) 33
analysis (31) 31
hygiene (31) 31
medical or veterinary science (31) 31
t (31) 31
cell line, tumor (30) 30
mutation (30) 30
separation (30) 30
chemical or physical processes, e.g. catalysis or colloidchemistry (29) 29
microbiology (29) 29
their relevant apparatus (29) 29
b-cell lymphoma (28) 28
tumor cells, cultured (28) 28
comparative genomic hybridization (27) 27
lymphoma, large b-cell, diffuse - genetics (27) 27
translocation (27) 27
child (25) 25
amino acid sequence (24) 24
apoptosis (24) 24
gene expression profiling (24) 24
genes (24) 24
lymphoma, b-cell, marginal zone - genetics (24) 24
chromosome aberrations (23) 23
gene expression (22) 22
general tagging of cross-sectional technologies spanning over several sections of the ipc (22) 22
general tagging of new technological developments (22) 22
measuring (22) 22
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (22) 22
testing (22) 22
amplification (21) 21
beer (21) 21
biochemistry (21) 21
dna-binding proteins - genetics (21) 21
electricity (21) 21
enzymology (21) 21
mutation or genetic engineering (21) 21
oligonucleotide array sequence analysis (21) 21
organic chemistry (21) 21
proto-oncogene proteins - genetics (21) 21
spirits (21) 21
tumors (21) 21
vehicles in general (21) 21
vinegar (21) 21
wine (21) 21
article (20) 20
cell line (20) 20
ferrous or non-ferrous alloys (20) 20
gene expression regulation, neoplastic (20) 20
lymphoma - genetics (20) 20
preparations for medical, dental, or toilet purposes (20) 20
treatment of alloys or non-ferrous metals (20) 20
alloys (19) 19
cell biology (19) 19
cloning (19) 19
general devices for heat treatment of ferrous or non-ferrousmetals or alloys (19) 19
in situ hybridization, fluorescence (19) 19
information storage (19) 19
information storage based on relative movement between recordcarrier and transducer (19) 19
making metal malleable by decarburisation, tempering or othertreatments (19) 19
medical colleges (19) 19
metallurgy of iron (19) 19
modifying the physical structure of ferrous metals (19) 19
reverse transcriptase polymerase chain reaction (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (802) 802
Japanese (39) 39
German (23) 23
Spanish (20) 20
French (12) 12
Chinese (5) 5
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 07/2014, Volume 105, Issue 7, pp. 897 - 904
Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T‐cell lymphoma/leukemia, peripheral T‐cell lymphoma, not otherwise... 
Array comparative genomic hybridization | tumor cell population | malignant lymphoma | heterogeneity | patient outcome assessment | Patient outcome assessment | Heterogeneity | Malignant lymphoma | Tumor cell population | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | MARGINAL ZONE | CANCER | SOMATIC MUTATIONS | B-CELL LYMPHOMA | EVOLUTION | ONCOLOGY | CODING GENOME | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMPARATIVE GENOMIC HYBRIDIZATION | CHROMOSOMAL IMBALANCES | Prognosis | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Humans | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Lymphoma - genetics | Lymphoma, Follicular - mortality | Chromosomes, Human, Pair 8 | Gene Dosage | Lymphoma - mortality | Lymphoma, B-Cell, Marginal Zone - mortality | Burkitt Lymphoma - mortality | Lymphoma, B-Cell, Marginal Zone - genetics | Burkitt Lymphoma - pathology | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Follicular - genetics | Comparative Genomic Hybridization | Gene Deletion | Burkitt Lymphoma - genetics | Lymphoma - pathology | Lymphoma, B-Cell, Marginal Zone - pathology | Lymphoma, Large B-Cell, Diffuse - genetics | Cell survival | p53 Protein | Cloning | Hybridization | Myc protein | Clinical outcomes | Ratios | Lymphocytes B | Mantle cell lymphoma | Cell cycle | Hybridization analysis | Biomarkers | Population | Lymphomas | Mutation | Chromosomes | Tumors | Apoptosis | Original
Journal Article
Cancer Science, ISSN 1347-9032, 04/2015, Volume 106, Issue 4, pp. 344 - 351
Recent advances in treatment for adult T‐cell leukemia‐lymphoma (ATL) are reviewed herein. It is currently possible to select a therapeutic strategy for ATL... 
molecular targeted therapy | chemotherapy | Adult T‐cell leukemia‐lymphoma | antiviral therapy | allogeneic hematopoietic stem cell transplantation | Molecular targeted therapy | Antiviral therapy | Chemotherapy | Allogeneic hematopoietic stem cell transplantation | Adult T-cell leukemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | TRANSPLANTATION | INTERFERON-ALPHA | ONCOLOGY | VIRUS TYPE-I | JAPAN | GROWTH | LEUKEMIA/LYMPHOMA | HTLV-1 | EXPRESSION | ASSOCIATION | Cell- and Tissue-Based Therapy - methods | Leukemia-Lymphoma, Adult T-Cell - diagnosis | Immunotherapy - methods | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, CCR4 - immunology | Antiviral Agents - therapeutic use | Humans | Leukemia-Lymphoma, Adult T-Cell - mortality | Interferon-alpha - therapeutic use | Hematopoietic Stem Cell Transplantation | HTLV-I Infections - drug therapy | Receptors, CCR4 - antagonists & inhibitors | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Zidovudine - therapeutic use | Human T-lymphotropic virus 1 - genetics | Reverse Transcriptase Inhibitors - therapeutic use | Molecular Targeted Therapy - methods | Dehydrogenases | Breastfeeding & lactation | Leukemia | Mortality | Cloning | Stem cell transplantation | Cytotoxicity | Infections | Histology | Lymphoma | Patients | Hematopoietic stem cells | Hemopoiesis | Prevention | Lymphocytes | Medical prognosis | Monoclonal antibodies | Lymphomas | Interferon | Trends | Zidovudine | Review
Journal Article
Blood, ISSN 0006-4971, 02/2013, Volume 121, Issue 8, pp. 1249 - 1250
In this issue of Blood, Salaverria et al report that more than half of Cyclin D1- (CCND1) negative SOX11-positive mantle cell lymphoma (MCL) had CCND2 gene... 
HEMATOLOGY | EXPRESSION | Cyclin D2 - genetics | Cyclin D1 - genetics | Humans | Lymphoma, Mantle-Cell - pathology | Female | Male | Gene Rearrangement - genetics | Lymphoma, Mantle-Cell - genetics
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 03/2010, Volume 101, Issue 3, pp. 573 - 578
Journal Article
STEM CELLS, ISSN 1066-5099, 02/2013, Volume 31, Issue 2, pp. 236 - 247
The initial steps involved in the pathogenesis of acute leukemia are poorly understood. The TEL‐AML1 fusion gene usually arises before birth, producing a... 
Acute lymphocytic leukemia | Self‐renewal | Cancer stem cells | B lymphocytes | Self-renewal | T(12/21) | TEL-AML1 FUSION | CANCER | CELL & TISSUE ENGINEERING | CELL BIOLOGY | RELAPSE | ORIGINS | GENE | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | DIFFERENTIATION | HEMATOLOGY | EXPRESSION | HEMATOPOIETIC STEM | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Gene Expression Regulation, Neoplastic | Precursor Cells, B-Lymphoid - immunology | Gene Expression Profiling | Homeodomain Proteins - immunology | HMGB3 Protein - genetics | Oncogene Proteins, Fusion - immunology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology | Cell Cycle Proteins - immunology | Precursor Cells, B-Lymphoid - pathology | Proto-Oncogene Proteins - immunology | Trans-Activators - genetics | Cell Cycle Proteins - genetics | Fetus | Transcription, Genetic | Embryonic Stem Cells - immunology | Trans-Activators - immunology | Signal Transduction | Protein-Serine-Threonine Kinases - genetics | Repressor Proteins - genetics | HMGB3 Protein - immunology | Proto-Oncogene Proteins - genetics | Homeodomain Proteins - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Animals | Core Binding Factor Alpha 2 Subunit - immunology | Oncogene Proteins, Fusion - genetics | Repressor Proteins - immunology | Embryonic Stem Cells - pathology | Lymphocyte Count | Protein-Serine-Threonine Kinases - immunology | Mice | Mice, Inbred BALB C | Core Binding Factor Alpha 2 Subunit - genetics | Bone marrow | Stem cells
Journal Article
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 12, pp. 3195 - 3204
Journal Article
Methods in molecular biology (Clifton, N.J.), ISSN 1064-3745, 2013, Volume 973, pp. 189 - 196
Journal Article
Cancer Science, ISSN 1347-9032, 08/2016, Volume 107, Issue 8, pp. 1072 - 1078
Adult T‐cell leukemia/lymphoma (ATL) develops in human T‐cell leukemia virus type 1 (HTLV‐1) carriers. Although the HTLV‐1‐encoded HBZ gene is critically... 
HBZ | ATL | AKT | mouse model | BCLxL | GENE | ONCOLOGY | LYMPHOMA | LEUKEMIA/LYMPHOMA | PROLIFERATION | MICE | FEATURES | Interleukins | T cells | Analysis | Leukemia | Cytokines | Genes | AKT protein | Lymphocytes T | Transplantation | Kinases | Lymphoma | Plasmids | Lymphocytes | Transgenic animals | Collaboration | Cooperation | Rodents | Ligands | Lymphomas | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 05/2014, Volume 105, Issue 5, pp. 537 - 544